Evaluation of lightweight fibreglass heel casts in the management of ulcers of the heel in diabetes

A lightweight fibreglass heel cast, thin enough to fit inside a normal shoe, is being tested against standard care for diabetic heel ulcers. This matters because heel ulcers in people with diabetes are notoriously slow to heal and often lead to infection, amputation, or prolonged immobility. Existing casts are bulky, prevent patients from wearing usual footwear, and can cause further skin damage. The fibreglass design is a practical alternative that observational data suggest speeds healing and reduces discomfort. If the trial confirms these benefits, the cast could become a standard, low-cost tool in diabetic foot clinics. Patients would be able to walk more comfortably during treatment, potentially shortening healing times and reducing hospital visits. The impact would be felt directly in everyday life—fewer amputations, less time off work, and simpler wound management for community nurses. The research is a randomised controlled trial across 25 to 30 UK centres. Patients receive either the cast or standard care, with fortnightly reviews until the ulcer heals or for up to 24 weeks. This is a pragmatic, applied study with a clear endpoint: does a better-fitting cast actually heal more ulcers?